<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301130</url>
  </required_header>
  <id_info>
    <org_study_id>0761-012</org_study_id>
    <nct_id>NCT02301130</nct_id>
  </id_info>
  <brief_title>Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors</brief_title>
  <official_title>Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Pharmaceutical Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyowa Kirin Pharmaceutical Development, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with
      Tremelimumab in Subjects with Advanced Solid Tumors
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2014</start_date>
  <completion_date type="Actual">March 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects reporting adverse events</measure>
    <time_frame>Screening through 90 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting serious adverse events</measure>
    <time_frame>Screening through 90 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting serious adverse events</measure>
    <time_frame>Screening through 90 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting adverse events</measure>
    <time_frame>Screening through 90 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing dose-limiting toxicity</measure>
    <time_frame>First dose of study medications through 4 weeks after the last dose of study medication</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>mogamulizumab + MEDI4736 (Durvalumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Parts 1 and 2, mogamulizumab and MEDI4736 (Durvalumab) are administered at appropriate intervals.
Part 1 (Dose Escalation Phase)
- During Cohort 1A to 4A, increased doses of mogamulizumab and MEDI4736 (Durvalumab) are administered.
Part 2 (Cohort Expansion Phase)
Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mogamulizumab + tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Parts 1 and 2, mogamulizumab and tremelimumab are administered at appropriate intervals.
Part 1 (Dose Escalation Phase)
- During Cohort 1B to 4B, increased doses of mogamulizumab and tremelimumab are administered.
Part 2 (Cohort Expansion Phase)
Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mogamulizumab</intervention_name>
    <description>Mogamulizumab will be administered intravenously (IV).</description>
    <arm_group_label>mogamulizumab + MEDI4736 (Durvalumab)</arm_group_label>
    <arm_group_label>mogamulizumab + tremelimumab</arm_group_label>
    <other_name>KW-0761</other_name>
    <other_name>POTELIGEO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736 (Durvalumab)</intervention_name>
    <description>MEDI4736 will be administered intravenously (IV).</description>
    <arm_group_label>mogamulizumab + MEDI4736 (Durvalumab)</arm_group_label>
    <other_name>Durvalumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tremelimumab</intervention_name>
    <description>Tremelimumab will be administered intravenously (IV).</description>
    <arm_group_label>mogamulizumab + tremelimumab</arm_group_label>
    <other_name>ticilimumab</other_name>
    <other_name>CP-675,206</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years;

          -  Locally advanced or metastatic solid tumors;

          -  Histologically or cytologically confirmed disease;

          -  Failed or were intolerant to at least one prior systemic treatment regimen with oral
             or IV medications and have no additional therapy options known to prolong survival
             with the exception of PD-1 or PD-L1 blockade therapy for subjects who will be enrolled
             in treatment arm A. Subjects with non-small cell lung cancer must have received at
             least one platinum doublet regimen. Subjects with known epidermal growth factor
             receptor tyrosine kinase inhibitor activating mutations or anaplastic lymphoma kinase
             rearrangement must have also exhausted approved targeted therapy options;

          -  The subject has a tumor suitable for biopsy and is willing to undergo tumor biopsy,
             preferably of the primary tumor, within 28 days prior to Cycle 1/Visit Day 1;

        Exclusion Criteria:

          -  Any concurrent chemotherapy, biologic, hormonal, radiation, or investigative therapy
             for cancer treatment within 21 days prior prior or within 6 weeks prior to Cycle
             1/Visit Day 1 for nitrosoureas or mitomycin C;

          -  Concurrent or prior use of immunosuppressive medication within 28 days;

          -  Active or prior documented autoimmune, or inflammatory bowel disease, or inflammatory
             bowel disease. or systemic treatment for psoriasis within the past 5 years.;

          -  Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins,
             or immunotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Angeles Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid tumors</keyword>
  <keyword>solid tumors</keyword>
  <keyword>mogamulizumab</keyword>
  <keyword>MEDI4736 (Durvalumab)</keyword>
  <keyword>Tremelimumab</keyword>
  <keyword>POTELIGEO®</keyword>
  <keyword>KW-0761</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

